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VIEWPOINTS
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Abstract
Summary Asia Pacific Consortium on Osteoporosis (APCO) comprises of clinical experts from across the Asia Pacific region,
uniting to develop solutions to problems facing osteoporosis management and care. The vision of APCO is to reduce the burden
of osteoporosis and fragility fractures in the Asia Pacific region.
Introduction The Asia Pacific (AP) region comprises 71 countries with vastly different healthcare systems. It is predicted that by
2050, more than half the world’s hip fractures will occur in this region. The Asia Pacific Consortium on Osteoporosis (APCO)
was set up in May 2019 with the vision of reducing the burden of osteoporosis and fragility fractures in the AP region.
Methods APCO has so far brought together 39 clinical experts from countries and regions across the AP to develop solutions to
challenges facing osteoporosis management and fracture prevention in this highly populous region of the world. APCO aims to
achieve its vision by engagingwith relevant stakeholders including healthcare providers, policymakers and the public. The initial
APCO project is to develop and implement a Framework of pan-AP minimum clinical standards for the screening, diagnosis and
management of osteoporosis.
Results and conclusions The Framework will serve as a platform upon which new national clinical guidelines can be developed
or existing guidelines be revised, in a standardised fashion. The Framework will also facilitate benchmarking for provision of
quality of care. It is hoped that the principles underlying the formation and functioning of APCO can be adopted by other regions
and that every health care facility and progressively every country in the world can follow our aspirational path and progress
towards best practice.
Keywords Osteoporosis . Fragility fracture . Quality improvement . Clinical standards . Collaboration . Asia Pacific
A fragility fracture signals underlying osteoporosis, a condi-
tion that is greatly underdiagnosed and undertreated. The
burden of osteoporosis is expected to increase as populations
age, and the number of individuals at risk of fragility fractures
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worldwide is estimated to increasemore than twofold from the
158 million it was in 2010 to 319 million by the year 2040 [1].
Unfortunately, even the patients at highest risk who have al-
ready fractured are often not treated [2, 3]. The situation, in the
Asia Pacific region, which is home to 4.5 billion people and
comprises 71 countries and regions [4] is going to be even
more overwhelming. The population aged over 65 years in
Asia alone is projected to more than quadruple by 2050, and
to further grow by almost sixfold by the year 2100 [5]. It is
predicted that in the year 2050, over half of the world’s hip
fractures will be in the Asia Pacific region [6]. This will come
at great cost; treating a single hip fracture represents approx-
imately 19% of Asia Pacific’s regional per-head gross domes-
tic product each year even currently [7, 8].
Despite the enormous and growing burden of fragility
fractures, osteoporosis is being dangerously ignored as
it competes with other diseases for scarce health-care
resources and recognition. The disease remains greatly
under-diagnosed and under-treated, and health profes-
sional training and service provision is suboptimal in
many countries of the Asia Pacific. – Professor John
Kanis, Honorary President, International Osteoporosis
Foundation (IOF) at the launch of the Asia Pacific
Regional Audit Report, 2013 [9]
This statement comes as no surprise since the Asia Pacific
region has within it, populations with tremendously diverse
socio-economic and cultural norms and countries with vastly
different health systems and resources. The healthcare re-
sponses to osteoporosis are thus fragmented and unequal.
Added challenges include variations in knowledge and dis-
ease awareness, limited diagnostic facilities and lack of health
professionals trained in osteoporosis management in several
countries in the region [3, 10, 11].
The Asia Pacific Consortium on Osteoporosis
The Asia Pacific Consortium on Osteoporosis (APCO), a non-
partisanal and apolitical organization, was established in
May 2019with the vision of reducing the burden of osteoporosis
and fragility fractures in the Asia Pacific region. APCO hopes to
achieve this vision by engaging with relevant stakeholders in-
cluding healthcare providers, policy makers and the public, to
help develop and implement country and region-specific pro-
grams for the prevention and treatment of osteoporosis and its
complication of fragility fractures in the Asia Pacific region.
The idea for developing a consortium on osteoporosis was
inspired by similar work in another area of clinical medicine.
The primary aim at the time of the formation of APCO was to
gather a group of experts whose work to date has demonstrat-
ed their passion and commitment to advancing the cause of
osteoporosis in their respective countries and/or in the region.
These individuals were identified and invited by the
Chairperson to contribute their expertise to APCO. APCO
members voluntarily contribute their time and expertise to it.
The strength of APCO lies in the diversity of its members,
with it creating a forum for the exchange of ideas between
experts working in very different healthcare systems and clin-
ical settings. APCO is also ably supported in its functions by a
four-member project management team.
APCO currently has 39 experts from 19 countries and re-
gions within the Asia Pacific. The International Osteoporosis
Foundation (IOF) is represented by its Chief Executive Officer.
We hope to ultimately include osteoporosis experts from all the
countries and regions in the Asia Pacific. APCO endeavours to
support and empower healthcare professionals to improve os-
teoporosis care, and its members will serve as a bridge between
APCO and their colleagues, thought leaders, osteoporosis so-
cieties and policy makers within their respective countries.
The priority initiative of APCO
Adherence to evidence-based management recommendations
is associated with improvement in patient outcomes [12].
Strategies employed to improve the implementation and use
of osteoporosis guidelines have also been shown to result in
management plans becoming aligned with best practice [13].
APCO has identified the following key gaps in osteoporosis
screening, diagnosis and in consistent delivery of osteoporosis
care in the Asia Pacific region:
& Clinical guidelines relating to osteoporosis in the Asia
Pacific are either unavailable and if they are, are heterog-
enous in terms of their scope and recommendations made.
& A significant proportion of current national guide-
lines are not current, having been published more
than 10 years ago.
& There is a paucity of information on adherence with na-
tional guidelines in day-to-day clinical practice across the
region.
Therefore, APCO’s first project is to develop and imple-
ment a Pan-Asia Pacific framework (“The Framework”) that
provides clinical standards for the screening, diagnosis and
management of osteoporosis in groups at high risk of fracture.
Broad endorsement of the Framework will be sought from
national and international organizations before publication of
the Framework. Subsequently, APCO will also provide tools
and templates to support its members to deliver the
Framework at the local level. The long-term goal after publi-
cation of the Framework is to develop APCO into a free-
standing entity with a formalized legal, governance and orga-
nizational structure.
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The nitty-gritties of developing
The Framework
The framework focuses on identifying and treating a broad
range of high-risk groups in a tiered manner. The highest pri-
ority group is older men and post-menopausal women with a
prevalent fragility fracture. The other groups that are included
in the Framework are people taking medications and/or have
medical conditions that predispose them to bone loss or fragility
fracture, people deemed to be at high risk based on country-
specific fracture intervention thresholds, those aged 70 years or
over and those below 70 years of age with other risk factors for
fragility fracture, such as a history of frequent falls.
A stepwise approach informed by analogous approaches
undertaken elsewhere [14] is being employed to develop the
Framework. All osteoporosis and fracture prevention guide-
lines published in the last decade in the Asia Pacific region
have been identified and those in other languages have been
translated into English. A comparative analysis of the guide-
lines with special attention to the ones published in the last
quinquennium has been done using a template based on a
modified “5IQ” approach. The “5IQ” approach underpinned
the development of clinical standards for Fracture Liaison
Services (FLS) in New Zealand [15] and the UK [16]. Each
guideline that was included in the comparative analysis was
thoroughly evaluated to see whether the following 6 parame-
ters were included in it:
& Identification: a statement regarding which individuals are
identified as high risk
& Investigation: a description of the types of investigations
recommended to delineate the cause of osteoporosis
& Information: a description of the types of education that
are provided
& Initiation: a description of pharmacological and falls pre-
vention interventions
& Integration: a statement on the need for integration be-
tween primary and secondary care
& Quality: a description of professional development, audit
and peer-review activities
The comparative analysis has now been completed. The
minimum standards of care that will form the framework will
be generated through a Delphi process [17] to identify areas of
consensus and discord amongst the APCO members.
The Framework will serve as a platform upon which new
national clinical guidelines in the Asia Pacific can be devel-
oped or existing guidelines be revised, in a standardized fash-
ion. Practical adoption of the clinical standards at each nation-
al level is the ultimate purpose for developing the Framework.
Notably, the Framework will be a distilled guidance document
with minimum clinical standards for best practice, not a pre-
scriptive guideline.
To address the heterogeneity across the region, the
Framework and its implementation will be modular,
allowing the user to select the most appropriate content
depending on the stage or level already attained by their
facility or country. A stepwise path for progression to-
wards best practice will be set, and each facility will be
encouraged to progress to the next level as they are able
to. This modular approach is similar to the Capture the
Fracture® Best Practice Framework that has been imple-
mented by the IOF and to the patient-level key perfor-
mance indicators recently endorsed by the National
Osteoporosis Foundation and the Fragility Fracture
Network [18, 19].
For each country or region, an assessment of the differ-
ences between the core recommendations of current national
clinical guidelines and the standards advocated in the
Framework will inform the improvements that need to be
made at the national /regional level. This can then serve as
an impetus to advocate for and to drive policy change. To
realise these changes, APCO will be collaborating with na-
tional, regional and international societies and organizations
such as the Asian Federation of Osteoporosis Societies, the
Fragility Fracture Network, the Asia Pacific Fragility Fracture
Alliance and the International Osteoporosis Foundation and
educational initiatives such as the Asia Pacific Bone Academy
[20].We envision these collaborations to be seamless as many
of the APCO members are already part of these organisations
and initiatives.
Implementation of the Framework and its effectiveness
needs to be measured for it to be meaningful. The medical
centres where APCO members work at will serve as “path-
finder” sites for their respective countries. Immediately after
publication of the Framework, an audit will be conducted at
pathfinder sites to assess how congruent their own standards
of care are with those advocated in the Framework. A follow-
up audit can then be conducted by pathfinder sites 12 months
after the baseline audit, to assess the impact of the Framework.
In the words of the Chinese philosopher, Lao Tzu (老
子《道德經), “The journey of a thousand miles starts with
one step” (“「千里之行, 始於足下」”). There is no doubt that
there is a long way to go to reduce the burden of osteoporosis
and fragility fractures in the Asia Pacific region. The develop-
ment of the Framework of minimum clinical standards is the
first step to improve the screening, diagnosis and management
of osteoporosis in groups at high risk of fracture in this region.
APCO’s intention is not to ignore current stark realities and
the challenges and limitations that make osteoporosis care
difficult in such a vast and diversely populated area such as
the Asia Pacific, but to provide a benchmark to which organi-
zations and health care facilities can aspire. The principles
underlying the formation and functioning of APCO could po-
tentially be adopted by other regions in the world. It is hoped
that each facility and progressively each country will follow
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our aspirational path towards best practice, ultimately making
osteoporosis a national, regional and international health pri-
ority to avert the “perfect storm” [3] that is brewing.
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